NAS
NKTR icon

Nykredit A/S’s Nektar Therapeutics NKTR Stock Holding History

Nykredit A/S’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Buy
+209
New +$15.3K ﹤0.01% 1809

Other funds holding NKTR

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's NKTR Position: Q2 2026 in Review

Nykredit A/S opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 209 shares worth $14.6K. The stake represents ﹤0.01% of the portfolio and ranks #1809 among its holdings.

144 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Nykredit A/S held 209 shares of Nektar Therapeutics worth $14.6K as of Q2 2026.
  • Nektar Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1809 holding.
  • 144 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.